Suzhan Zhang
Overview
Explore the profile of Suzhan Zhang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
92
Citations
1567
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wang F, Chen G, Zhang Z, Yuan Y, Wang Y, Gao Y, et al.
Cancer Commun (Lond)
. 2024 Dec;
PMID: 39739441
The 2024 updates of the Chinese Society of Clinical Oncology (CSCO) Clinical Guidelines for the diagnosis and treatment of colorectal cancer emphasize standardizing cancer treatment in China, highlighting the latest...
2.
Wang J, Li B, Luo M, Huang J, Zhang K, Zheng S, et al.
Signal Transduct Target Ther
. 2024 Apr;
9(1):83.
PMID: 38570490
Ductal carcinoma in situ (DCIS) represents pre-invasive breast carcinoma. In untreated cases, 25-60% DCIS progress to invasive ductal carcinoma (IDC). The challenge lies in distinguishing between non-progressive and progressive DCIS,...
3.
Zhang X, Zhu R, Jiao Y, Simayi H, He J, Shen Z, et al.
PeerJ
. 2024 Apr;
12:e17105.
PMID: 38563016
Background: Colorectal cancer (CRC) is one of the most common cancers worldwide and is related to diet and obesity. Currently, crosstalk between lipid metabolism and CRC has been reported; however,...
4.
Fang X, Zhu N, Zhong C, Wang L, Li J, Weng S, et al.
EClinicalMedicine
. 2023 Aug;
62:102123.
PMID: 37554125
Background: Microsatellite stable (MSS) and RAS-mutant metastatic colorectal cancer (mCRC) patients are characterized by an immunosuppressive microenvironment and a low response rate to immunotherapy. Chemotherapy and anti-angiogenesis therapy have been...
5.
Hong M, Du Y, Chen D, Shi Y, Hu M, Tang K, et al.
Sci Bull (Beijing)
. 2023 Jul;
68(15):1662-1677.
PMID: 37481436
Martynoside (MAR), a bioactive component in several well-known tonic traditional Chinese herbs, exhibits pro-hematopoietic activity during 5-fluorouracil (5-FU) treatment. However, the molecular target and the mechanism of MAR are poorly...
6.
Fang X, Zhong C, Weng S, Hu H, Wang J, Xiao Q, et al.
BMC Cancer
. 2023 Jul;
23(1):676.
PMID: 37464378
Background: Rat sarcoma viral oncogene homolog (RAS) gene mutation is a common molecular event in colorectal cancer (CRC). The prognosis of mCRC (metastatic colorectal cancer) patients with RAS mutation is...
7.
Pan T, Hu Z, Xu D, Zhou Y, Zhang S, Chen Y
Medicine (Baltimore)
. 2023 Jun;
102(24):e34018.
PMID: 37327286
The objective of this study is to assess the predictive potency of cell senescence-related genes (CSRGs) in breast cancer (BC) and establish a risk signature. Trascriptome data of CSRGs were...
8.
Wang K, Shen L, Tian W, Zhang S
Sci Rep
. 2022 Dec;
12(1):22650.
PMID: 36587111
Adjuvant endocrine therapy improves the prognosis of early breast cancer with hormone receptor positivity. However, there is no systematic report on the effect of endocrine therapy (particularly ovarian function suppression,...
9.
Fu X, Ying J, Yang L, Fang W, Han W, Hu H, et al.
Cancer Sci
. 2022 Nov;
114(3):1067-1074.
PMID: 36382603
This trial was initiated to evaluate the efficacy and safety of pyrotinib in combination with trastuzumab in patients with human epidermal growth factor receptor 2 (HER2)-positive recurrent/metastatic colorectal cancer (CRC)....
10.
Zhang J, Wu Y, Mu J, Xin D, Wang L, Fan Y, et al.
Front Oncol
. 2022 Oct;
12:954226.
PMID: 36203430
Purpose: Colon adenocarcinoma (COAD) is the most common type of colorectal cancer (CRC) and is associated with poor prognosis. Emerging evidence has demonstrated that glycosylation by long noncoding RNAs (lncRNAs)...